Evaluation of Ablation Index and VISITAG™ Use for Pulmonary Vein Isolation (PVI) in Patients With Paroxysmal Atrial Fibrillation (PAF)
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 340
- 试验地点
- 17
- 主要终点
- Incidence of primary adverse events
研究概览
简要总结
The purpose of this study is to assess the safety, acute and long term effectiveness, during standard RF ablation procedures while using Ablation Index and VISITAG™ software in combination with a Thermocool SmartTouch® (ST) or SmartTouch Surroundflow® (STSF) catheter. Furthermore, the role of Ablation Index and VISITAG™ workflow in creating contiguous ablation lines is assessed. The study is a prospective, non-randomized, post-market clinical evaluation. Up to 330 patients will be included in this study. All patients who qualify based on the study specific requirements will be invited to participate. The total duration of the study is estimated to be about 24 months (12 months enrollment period and 12 months of follow up). The clinical investigation population include subjects undergoing RF ablation for treatment of drug resistant symptomatic paroxysmal AF. Prior to enrollment in the clinical investigation, all subjects must meet the inclusion/exclusion criteria and are suitable candidates for enrollment in a clinical investigation in the opinion of the investigator. Subjects must have failed at least one antiarrhythmic drug (AAD) (Type I or III, including β-blocker) as evidenced by recurrent or are intolerant of the AAD.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Symptomatic paroxysmal AF who had at least one AF episode electrocardiographically documented within one (1) year prior to enrollment. Documentation may include electrocardiogram (ECG); Transtelephonic monitoring (TTM), holter monitor or telemetry strip
- •Failed at least one antiarrhythmic drug (AAD) (Type I or III, including β-blocker) as evidenced by recurrent symptomatic AF, or intolerance to the AAD
- •Age 18 years or older
- •Signed Patient Informed Consent Form (ICF)
- •Able and willing to comply with all pre-, post-, and follow-up testing and requirements
排除标准
- •Atrial fibrillation secondary to electrolyte imbalance, thyroid disease, or reversible or non-cardiac cause.
- •Previous LA ablation or surgery
- •Anticipated to receive ablation outside the PV ostia and CTI region
- •Previously diagnosed with persistent AF (> 7 days in duration)
- •LA size >50 mm
- •LA thrombus
- •LVEF < 40%
- •Uncontrolled heart failure or NYHA Class III or IV
- •History of blood clotting, bleeding abnormalities or contraindication to anticoagulation (heparin, warfarin, or dabigatran)
- •History of a documented thromboembolic event (including TIA) within the past 6 months
- •Previous PCI/MI within the past 3 months
- •Previous cardiac surgery (e.g. CABG) within the past 6 months
- •Previous valvular cardiac surgical/percutaneous procedure (e.g. ventriculotomy, atriomy, valve repair or replacement, presence of a prosthetic valve)
- •Unstable angina pectoris
- •Awaiting cardiac transplantation, cardiac surgery or other major surgery within the next 12 months.
- •Significant pulmonary disease (e.g., restrictive pulmonary disease, constrictive or chronic obstructive pulmonary disease) or any other disease or malfunction of the lungs or respiratory system that produces chronic symptoms
- •Acute illness, active systemic infection or sepsis
- •Presence of intracardiac thrombus, myxoma, tumor, interatrial baffle or patch or other abnormality that precludes catheter introduction or manipulation.
- •Presence of a condition that precludes vascular access
- •Significant congenital anomaly or a medical problem that in the opinion of the investigator would preclude enrollment in this trial
- •Current enrollment in an investigational study evaluating another device or drug.
- •Women who are pregnant (as evidenced by pregnancy test if pre-menopausal)
- •Life expectancy less than 12 months
- •Presenting contra-indications for the devices used in the study, as indicated in the respective Instructions For Use
研究组 & 干预措施
RF ablation
Subjects undergoing RF ablation with the Thermocool SmartTouch® (ST) or SmartTouch Surroundflow® (STSF) catheter for treatment of drug resistant symptomatic paroxysmal AF
干预措施: RF ablation (Device)
结局指标
主要结局
Incidence of primary adverse events
时间窗: 7 days
A Primary adverse event (PAE) is a serious adverse event, which occurs within the first week (7 days) following an AF ablation procedure with use of ablation index.
confirmation of entrance block
时间窗: intraoperative
Presence/absence of acute reconnection will be evaluated through a 30 minute waiting period and adenosine challenge. PVs where acute reconnection is identified during the waiting period or following adenosine challenge will be considered ablation index false positives
long-term effectiveness
时间窗: 12 months
Freedom from documented atrial arrhythmia (atrial fibrillation (AF), atrial tachycardia (AT) or atrial flutter (AFL)) episodes (episodes ≥ 30 sec on arrhythmia monitoring device) during the effectiveness evaluation period (day 91-365)
次要结局
- Incidence of individual PAE versus total number of PAE(12 months)
- Incidence of entrance block after first encirclement (prior to 30-min waiting period)(intraoperative)
- Long-term effectiveness: freedom from documented symptomatic atrial arrhythmia(from 3 up to 12 months)